Up till now, FDA has only approved one drug, riluzole, for ALS which acts by delaying progression of the disease but has no assertive efficacy in increasing survival (Cheah et al., 2010). This authenticates the importance of iPS cell technology in providing a ray of hope for those patients who continue to suffer the lack of an effective remedy for their condition.
